Occupy Wall Street protester finds occupation on Wall St.

An independent broker-dealer has taken a flyer on an Occupy Wall Street protester.
NOV 29, 2011
An independent broker-dealer has taken a flyer on an Occupy Wall Street protester. John Thomas Financial has hired Tracy Postert, who has a doctorate in biomedical science, as an assistant to its chief market analyst, Wayne Kaufman. Ms. Postert, who specializes in pharmacology, got the job after he spotted her in October in front of the ragtag throng in the now-famous Zuccotti Park in New York's financial district. At the time, she was holding a handwritten sign that read: “Ph.D. Biomedical Scientist seeking full-time employment.” The back of the sign read: “Ask me for my résumé.” On Oct. 22, Mr. Kaufman did exactly that, and followed up the next day with an e-mail asking Ms. Postert to come in for an interview at John Thomas, an independent broker-dealer with more than 200 brokers. The company focuses on raising cash for start-ups and private deals.

AN UNUSUAL HIRE

Ms. Postert joined the anti-Wall Street movement in October and spent two weeks washing sidewalks and making sandwiches at Zuccotti Park, just two blocks from John Thomas' offices at 14 Wall St., according to the New York Post, which first reported the story last Monday. Mr. Kauffman said that he is “fascinated” by the Occupy Wall Street movement and had been making quick visits two or three times a week since the protest began in September to see what was happening at the park. The move to hire Ms. Postert is an effort to build up John Thomas' biotechnology business, he said. “I typically hire people out of business school,” Mr. Kaufman said. “They have MBAs and all that stuff.”

EXPERTISE IN SCIENCE

Ms. Postert, who is studying for her Series 7 exam, is a markedly different type of candidate, Mr. Kaufman said. Although she lacks experience reading financial statements, Ms. Postert has the scientific expertise to help uncover companies that are producing potentially winning drugs, he said. “We've bought a [biotech] stock at $3 per share, it went to $5 per share, and then we sold it. But the stock [eventually] went to $15 per share, and we didn't fully understand it,” Mr. Kaufman said. “She will help us understand what's going on at early-stage companies and ride them to big winners,” he said. Ms. Postert started at the firm Nov. 15. She said that she has been consistently underemployed since 1999 when she earned her degree in biomedical science with a specialization in pharmacology. Her last job was in the spring, Ms. Postert said. “I really like my [new] job, and that's not a BS statement,” Ms. Postert said. “I'm learning to evaluate companies on a financial basis, but I'm not there yet.”

LESS-KNOWN STOCKS

She is focusing on stocks of biotech companies that create drugs for diseases such as hepatitis C and cancer, as well as the extra-cellular matrix, which she describes as the connective “goo” outside animal cells. “Where I have an edge is with these up-and-coming biotech stocks,” Ms. Postert said. “If a company gets the science right, I'm going to like that company.” [email protected]

Latest News

The 2025 InvestmentNews Awards Excellence Awardees revealed
The 2025 InvestmentNews Awards Excellence Awardees revealed

From outstanding individuals to innovative organizations, find out who made the final shortlist for top honors at the IN awards, now in its second year.

Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty
Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty

Cresset's Susie Cranston is expecting an economic recession, but says her $65 billion RIA sees "great opportunity" to keep investing in a down market.

Edward Jones joins the crowd to sell more alternative investments
Edward Jones joins the crowd to sell more alternative investments

“There’s a big pull to alternative investments right now because of volatility of the stock market,” Kevin Gannon, CEO of Robert A. Stanger & Co., said.

Record RIA M&A activity marks strong start to 2025
Record RIA M&A activity marks strong start to 2025

Sellers shift focus: It's not about succession anymore.

IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients
IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients

Platform being adopted by independent-minded advisors who see insurance as a core pillar of their business.

SPONSORED Compliance in real time: Technology's expanding role in RIA oversight

RIAs face rising regulatory pressure in 2025. Forward-looking firms are responding with embedded technology, not more paperwork.

SPONSORED Advisory firms confront crossroads amid historic wealth transfer

As inheritances are set to reshape client portfolios and next-gen heirs demand digital-first experiences, firms are retooling their wealth tech stacks and succession models in real time.